ID   MG-63
AC   CVCL_0426
SY   M-G63; MG63
DR   BTO; BTO:0001596
DR   CLO; CLO_0007699
DR   CLO; CLO_0007701
DR   CLO; CLO_0050808
DR   EFO; EFO_0002234
DR   MCCL; MCC:0000323
DR   CLDB; cl3462
DR   CLDB; cl3463
DR   CLDB; cl3464
DR   CLDB; cl3465
DR   CLDB; cl4934
DR   AddexBio; C0004007/4991
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-1427
DR   BCRC; 60279
DR   BCRJ; 0173
DR   BioSample; SAMN03471910
DR   BioSample; SAMN03472771
DR   BioSample; SAMN10988146
DR   CCRID; 3111C0001CCC000080
DR   CCRID; 3131C0001000700124
DR   CCRID; 3142C0001000000073
DR   Cell_Model_Passport; SIDM00525
DR   ChEMBL-Cells; CHEMBL3308498
DR   ChEMBL-Targets; CHEMBL614347
DR   CLS; 300441/p2938_MG-63
DR   Cosmic; 755310
DR   Cosmic; 908131
DR   Cosmic; 931036
DR   Cosmic; 931913
DR   Cosmic; 1044085
DR   Cosmic; 1070844
DR   Cosmic; 1074394
DR   Cosmic; 1082504
DR   Cosmic; 1188475
DR   Cosmic; 1529903
DR   Cosmic-CLP; 908131
DR   DepMap; ACH-000359
DR   ECACC; 86051601
DR   GDSC; 908131
DR   GEO; GSM170251
DR   GEO; GSM320828
DR   GEO; GSM827317
DR   GEO; GSM879217
DR   GEO; GSM887314
DR   GEO; GSM888390
DR   GEO; GSM1670103
DR   GEO; GSM1915004
DR   GEO; GSM1915005
DR   GEO; GSM1915006
DR   GEO; GSM1915007
DR   GEO; GSM2635311
DR   GEO; GSM2635312
DR   GEO; GSM1915033
DR   GEO; GSM1915034
DR   IARC_TP53; 21498
DR   IARC_TP53; 21660
DR   ICLC; HTL99003
DR   IGRhCellID; MG63
DR   JCRB; IFO50108
DR   KCB; KCB 200528YJ
DR   KCLB; 21427
DR   LiGeA; CCLE_145
DR   Lonza; 872
DR   NCBI_Iran; C555
DR   PharmacoDB; MG63_924_2019
DR   RCB; RCB1890
DR   TKG; TKG 0294
DR   TOKU-E; 2429
DR   Wikidata; Q54905408
RX   PubMed=218153;
RX   PubMed=883813;
RX   PubMed=1577731;
RX   PubMed=2823272;
RX   PubMed=7873286;
RX   PubMed=8617485;
RX   PubMed=9144345;
RX   PubMed=9600771;
RX   PubMed=12645653;
RX   PubMed=15736406;
RX   PubMed=19160414;
RX   PubMed=19363654;
RX   PubMed=19787792;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=21519327;
RX   PubMed=22460905;
RX   PubMed=23129384;
RX   PubMed=24903274;
RX   PubMed=25382592;
RX   PubMed=25485619;
RX   PubMed=26320182;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=29334376;
RX   PubMed=30894373;
RX   PubMed=31068700;
CC   Group: Space-flown cell line (cellonaut).
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Characteristics: Can be induced to differentiate by treating the cells with 1,25-dihydroxyvitamin D3 and TGF-beta. The cells do not differentiate into the mineralized state, but stop at the matrix maturation stage (PubMed=1577731).
CC   Doubling time: 38 hours (PubMed=218153); 28.3 hours (PubMed=19363654).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Homozygous for CDKN2A deletion (PubMed=19787792; ATCC).
CC   Sequence variation: Has no TP53 mutation (PubMed=19787792).
CC   Omics: Array-based CGH.
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: H3K4me1 ChIP-seq epigenome analysis.
CC   Omics: H3K27ac ChIP-seq epigenome analysis.
CC   Omics: Metabolome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=3.1%; Native American=0.69%; East Asian, North=2.05%; East Asian, South=0%; South Asian=5.07%; European, North=23.83%; European, South=65.26% (PubMed=30894373).
CC   Anecdotal: Have been flown in space on Foton-10 and Foton-M3 to study if differentiation is altered in microgravity (PubMed=9144345; PubMed=9600771, PubMed=24903274).
CC   Caution: The reported STR profile from CLS of this cell line was changed in June 2019. Seven conflicts with other sources were resolved.
CC   Misspelling: MGG3; In figure 4 of PubMed=2823272.
ST   Source(s): AddexBio; ATCC; CCRID; CLS; Cosmic-CLP; ECACC; JCRB; KCLB; PubMed=19787792; PubMed=25877200; RCB; TKG
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 11
ST   D16S539: 11 (AddexBio; ATCC; CCRID; Cosmic-CLP; ECACC; PubMed=19787792; PubMed=25877200; RCB; TKG)
ST   D16S539: 11,12 (CLS; JCRB)
ST   D18S51: 16
ST   D19S433: 13,14
ST   D21S11: 30
ST   D2S1338: 17,24
ST   D3S1358: 15
ST   D5S818: 11,12
ST   D7S820: 10
ST   D8S1179: 13
ST   FGA: 21,25
ST   Penta D: 9,13
ST   Penta E: 11,12
ST   SE33: 20
ST   TH01: 9.3
ST   TPOX: 8,11
ST   vWA: 16,19
DI   NCIt; C9145; Osteosarcoma
DI   ORDO; Orphanet_668; Osteosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   14Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 12-03-20; Version: 32
RX   PubMed=218153; DOI=10.1159/000225298;
RA   Heremans H., Billiau A., Cassiman J.J., Mulier J.C., de Somer P.;
RT   "In vitro cultivation of human tumor tissues. II. Morphological and
RT   virological characterization of three cell lines.";
RL   Oncology 35:246-252(1978).
RX   PubMed=883813; DOI=10.1128/AAC.12.1.11;
RA   Billiau A., Edy V.G., Heremans H., Van Damme J., Desmyter J.,
RA   Georgiades J.A., De Somer P.;
RT   "Human interferon: mass production in a newly established cell line,
RT   MG-63.";
RL   Antimicrob. Agents Chemother. 12:11-15(1977).
RX   PubMed=1577731;
RA   Bonewald L.F., Kester M.B., Schwartz Z., Swain L.D., Khare A.,
RA   Johnson T.L., Leach R.J., Boyan B.D.;
RT   "Effects of combining transforming growth factor beta and
RT   1,25-dihydroxyvitamin D3 on differentiation of a human osteosarcoma
RT   (MG-63).";
RL   J. Biol. Chem. 267:8943-8949(1992).
RX   PubMed=2823272; DOI=10.1073/pnas.84.21.7716;
RA   Masuda H., Miller C., Koeffler H.P., Battifora H., Cline M.J.;
RT   "Rearrangement of the p53 gene in human osteogenic sarcomas.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:7716-7719(1987).
RX   PubMed=7873286; DOI=10.1016/8756-3282(94)90305-0;
RA   Clover J., Gowen M.;
RT   "Are MG-63 and HOS TE85 human osteosarcoma cell lines representative
RT   models of the osteoblastic phenotype?";
RL   Bone 15:585-591(1994).
RX   PubMed=8617485; DOI=10.1016/S0046-8177(96)90115-X;
RA   Scotlandi K., Serra M., Manara M.C., Benini S., Sarti M., Maurici D.,
RA   Lollini P.-L., Picci P., Bertoni F., Baldini N.;
RT   "Immunostaining of the p30/32MIC2 antigen and molecular detection of
RT   EWS rearrangements for the diagnosis of Ewing's sarcoma and peripheral
RT   neuroectodermal tumor.";
RL   Hum. Pathol. 27:408-416(1996).
RX   PubMed=9144345; DOI=10.1359/jbmr.1997.12.5.786;
RA   Carmeliet G., Nys G., Bouillon R.;
RT   "Microgravity reduces the differentiation of human osteoblastic MG-63
RT   cells.";
RL   J. Bone Miner. Res. 12:786-794(1997).
RX   PubMed=9600771; DOI=10.1016/S8756-3282(98)00007-6;
RA   Carmeliet G., Nys G., Stockmans I., Bouillon R.;
RT   "Gene expression related to the differentiation of osteoblastic cells
RT   is altered by microgravity.";
RL   Bone 22:139S-143S(1998).
RX   PubMed=12645653; DOI=10.1016/S0165-4608(02)00685-4;
RA   Ozaki T., Neumann T., Wai D.H., Schaefer K.-L., van Valen F., Lindner N.,
RA   Scheel C., Bocker W., Winkelmann W., Dockhorn-Dworniczak B., Horst J.,
RA   Poremba C.;
RT   "Chromosomal alterations in osteosarcoma cell lines revealed by
RT   comparative genomic hybridization and multicolor karyotyping.";
RL   Cancer Genet. Cytogenet. 140:145-152(2003).
RX   PubMed=15736406;
RA   Pautke C., Schieker M., Tischer T., Kolk A., Neth P., Mutschler W.,
RA   Milz S.;
RT   "Characterization of osteosarcoma cell lines MG-63, Saos-2 and U-2 OS
RT   in comparison to human osteoblasts.";
RL   Anticancer Res. 24:3743-3748(2004).
RX   PubMed=19160414; DOI=10.1002/jcp.21667;
RA   Di Fiore R., Santulli A., Ferrante R.D., Giuliano M., De Blasio A.,
RA   Messina C., Pirozzi G., Tirino V., Tesoriere G., Vento R.;
RT   "Identification and expansion of human osteosarcoma-cancer-stem cells
RT   by long-term 3-aminobenzamide treatment.";
RL   J. Cell. Physiol. 219:301-313(2009).
RX   PubMed=19363654; DOI=10.1007/s10585-009-9259-6;
RA   Su Y.-X., Luo X.-J., He B.-C., Wang Y., Chen L., Zuo G.-W., Liu B.,
RA   Bi Y., Huang J.-Y., Zhu G.-H., He Y., Kang Q., Luo J.-Y., Shen J.-K.,
RA   Chen J., Jin X.-Q., Haydon R.C., He T.-C., Luu H.-H.;
RT   "Establishment and characterization of a new highly metastatic human
RT   osteosarcoma cell line.";
RL   Clin. Exp. Metastasis 26:599-610(2009).
RX   PubMed=19787792; DOI=10.1002/gcc.20717;
RA   Ottaviano L., Schaefer K.-L., Gajewski M., Huckenbeck W., Baldus S.,
RA   Rogel U., Mackintosh C., de Alava E., Myklebost O., Kresse S.H.,
RA   Meza-Zepeda L.A., Serra M., Cleton-Jansen A.-M., Hogendoorn P.C.W.,
RA   Buerger H., Aigner T., Gabbert H.E., Poremba C.;
RT   "Molecular characterization of commonly used cell lines for bone tumor
RT   research: a trans-European EuroBoNet effort.";
RL   Genes Chromosomes Cancer 49:40-51(2010).
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
RX   PubMed=21519327; DOI=10.1038/labinvest.2011.72;
RA   Mohseny A.B., Machado I., Cai Y., Schaefer K.-L., Serra M.,
RA   Hogendoorn P.C.W., Llombart-Bosch A., Cleton-Jansen A.-M.;
RT   "Functional characterization of osteosarcoma cell lines provides
RT   representative models to study the human disease.";
RL   Lab. Invest. 91:1195-1205(2011).
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
RX   PubMed=23129384; DOI=10.1002/jcp.24272;
RA   Di Fiore R., Fanale D., Drago-Ferrante R., Chiaradonna F.,
RA   Giuliano M., De Blasio A., Amodeo V., Corsini L.R., Bazan V.,
RA   Tesoriere G., Vento R., Russo A.;
RT   "Genetic and molecular characterization of the human osteosarcoma
RT   3AB-OS cancer stem cell line: a possible model for studying
RT   osteosarcoma origin and stemness.";
RL   J. Cell. Physiol. 228:1189-1201(2013).
RX   PubMed=24903274; DOI=10.1096/fj.14-249714;
RA   Guignandon A., Faure C., Neutelings T., Rattner A., Mineur P.,
RA   Linossier M.-T., Laroche N., Lambert C., Deroanne C., Nusgens B.,
RA   Demets R., Colige A., Vico L.;
RT   "Rac1 GTPase silencing counteracts microgravity-induced effects on
RT   osteoblastic cells.";
RL   FASEB J. 28:4077-4087(2014).
RX   PubMed=25382592; DOI=10.1021/pr500907d;
RA   Lamego I., Duarte I.F., Marques M.P.M., Gil A.M.;
RT   "Metabolic markers of MG-63 osteosarcoma cell line response to
RT   doxorubicin and methotrexate treatment: comparison to cisplatin.";
RL   J. Proteome Res. 13:6033-6045(2014).
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H.,
RA   Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y.,
RA   Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D.,
RA   Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D.,
RA   Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S.,
RA   Zhang Z.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
RX   PubMed=26320182; DOI=10.18632/oncotarget.5177;
RA   Ren L., Mendoza A., Zhu J., Briggs J.W., Halsey C., Hong E.S.,
RA   Burkett S.S., Morrow J., Lizardo M.M., Osborne T., Li S.Q., Luu H.H.,
RA   Meltzer P.S., Khanna C.;
RT   "Characterization of the metastatic phenotype of a panel of
RT   established osteosarcoma cells.";
RL   Oncotarget 6:29469-29481(2015).
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P.,
RA   Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
RX   PubMed=29334376; DOI=10.1038/nm.4475;
RA   Morrow J.J., Bayles I., Funnell A.P.W., Miller T.E., Saiakhova A.,
RA   Lizardo M.M., Bartels C.F., Kapteijn M.Y., Hung S., Mendoza A.,
RA   Dhillon G., Chee D.R., Myers J.T., Allen F., Gambarotti M., Righi A.,
RA   DiFeo A., Rubin B.P., Huang A.Y., Meltzer P.S., Helman L.J., Picci P.,
RA   Versteeg H.H., Stamatoyannopoulos J.A., Khanna C., Scacheri P.C.;
RT   "Positively selected enhancer elements endow osteosarcoma cells with
RT   metastatic competence.";
RL   Nat. Med. 24:176-185(2018).
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).